Selank: Clinical Guide for Prescribing Practices
Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been studied for anxiolytic and nootropic effects. It is approved as an anxiolytic in Russia.
Also Known As
How Selank Works
Selank modulates GABA-ergic neurotransmission and influences the balance of T-helper (Th1/Th2) cytokine expression, producing dual anxiolytic and immunomodulatory effects [2]. It enhances the expression of brain-derived neurotrophic factor (BDNF) and stabilizes enkephalin degradation, prolonging endogenous opioid peptide activity [1]. The peptide also influences serotonin metabolism, contributing to its anxiolytic profile without sedation or cognitive impairment [4].
Clinical Evidence
Russian clinical studies demonstrated Selank's anxiolytic effects comparable to benzodiazepines but without sedation, dependence potential, or cognitive impairment in patients with generalized anxiety disorder [4]. Uchakina et al. confirmed modulation of IL-6 and other inflammatory cytokines, supporting the immunomodulatory mechanism [2]. Preclinical research has shown BDNF upregulation in the hippocampus and frontal cortex, suggesting neuroprotective potential [3]. Selank received regulatory approval in Russia as an anxiolytic nasal spray (Selanc) based on Phase III clinical data [4].
Clinical Uses
Patient Selection and Screening
Appropriate candidates include patients with generalized anxiety disorder seeking non-benzodiazepine alternatives, individuals with cognitive complaints concurrent with anxiety [3], and those with immune dysregulation contributing to neuropsychiatric symptoms [2]. Contraindicated in pregnancy and lactation. Patients currently on immunosuppressive therapy should be monitored for immune-related interactions. It is not appropriate as monotherapy for severe psychiatric disorders.
Dosing and Administration
Intranasal administration is standard, with typical doses of 250 to 500 mcg per nostril, two to three times daily [4]. Treatment courses of 14 to 21 days are common, with periodic reassessment [2]. Some clinicians prescribe subcutaneous injection at 100 to 300 mcg daily for patients who prefer injection or have nasal absorption concerns. Cycling protocols (2 to 3 weeks on, 1 to 2 weeks off) are commonly employed. Dose should be titrated based on clinical response, starting at the lower range.
Route: Intranasal
Protocol notes: Typically administered intranasally. Dosing protocols vary by clinical indication.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Selank addresses the growing demand for non-addictive anxiolytic options, appealing to patients seeking alternatives to benzodiazepines and SSRIs. Its intranasal delivery eliminates injection barriers, improving patient compliance and accessibility. Practices combining Selank with Semax for cognitive and mood optimization can build complete nootropic protocols that drive patient retention and differentiation from standard psychiatric care.
FDA Category Status
Expected to return to Category 1 per February 2026 HHS announcement
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Selank through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
Is Selank approved for use in the United States?
References
- Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-7.
- Uchakina ON et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Bull Exp Biol Med. 2008;145(4):486-8.
- Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003;33(7):639-43.
- Seredenin SB et al. Anxiolytic effect of the Selank peptide analogue. Bull Exp Biol Med. 1998;125(2):173-5.
Related Peptides in Cognitive & Neurological
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Selank Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Selank Through Karpa